Blue Jet Healthcare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹376 Cr +127.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
BJ

Blue Jet Healthcare Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Blue Jet Healthcare Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹340Cr
+84.8% YoY
+6.9% QoQ
Net profit
₹110Cr
+175% YoY
+11.1% QoQ
Margin
41%
+12 pp YoY
+2 pp QoQ
Price₹596
Market cap₹11.1K Cr
P/E47.1

The short version

Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 cr. Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum.

From Blue Jet Healthcare Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 crore per quarter.
  • Contrast media segment depressed in H1 FY'25 but rebounded in H2; new product validations including NCE molecules contributing to growth expected in FY'26 and FY'27 (e.g., iodinated intermediate expected to ramp up fully in FY'27).
  • PI-API segment grew by 388% YoY, driven by advanced intermediates in cardiovascular therapy; order book fully served with new capacity at Ambernath.
  • Europe and Latin America markets for cardiovascular molecules growing faster than in the US.
  • Overall revenue grew 45% in FY'25; company aims to sustain growth momentum with strong customer demand, multi-year contracts, and capacity headroom.

2 more points from Blue Jet Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad.
  • Additional capacity being built at Mahad Unit-3, a continuous plant for KSM making, expected to go live in H2 FY'26.
  • Multipurpose Plant (MPP) under construction in Mahad, highly automated with ~30 reactors, capacity expected by second half of FY'27; CAPEX for MPP revised upwards to ~Rs. 300 crores.
  • State-of-the-art R&D center being built in Hyderabad at Rs. 40 crores, focusing on peptides, GLP-1 intermediates, biocatalysts.
  • Acquisition of land in GIDC Dahej, Gujarat for further expansion for CMI and pharma intermediates; timelines not yet firm.

2 more points from Blue Jet Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The current order book for pharma intermediates is fully served with new capacity added at Ambernath, resulting in a 388% jump compared to FY'24.
  • Supplies for an NCE molecule started in Q4, with expected linear order book growth aligned with this molecule's growth.
  • The iodinated intermediate is expected to launch in H1 FY'26, with full potential realization anticipated in FY'27.
  • Discussions with customers provide good demand visibility; the Company bases volume supply on these forecasts, not on external speculations.
  • Cardiovascular intermediate capacity utilization is about 60%-65%, indicating room for growth and readiness to capture demand upticks.

2 more points from Blue Jet Healthcare Ltd's call on order book

Create a free account to keep reading this call

Blue Jet Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Blue Jet Healthcare Ltd Q4 FY25 results — key figures

Blue Jet Healthcare Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue340184+84.8%318+6.9%
Operating profit (EBITDA)14053+164.2%124+12.9%
Operating margin41%29%+12 pp39%+2 pp
Profit before tax14754+172.2%132+11.4%
Net profit (PAT)11040+175%99+11.1%
EPS (₹)6.352.29+177.3%5.71+11.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Blue Jet Healthcare Ltd Q4 FY25 results?

Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 cr. Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum.

What is Blue Jet Healthcare Ltd share price analysis?

Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.

Is Blue Jet Healthcare Ltd planning capital expenditure?

Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad.

Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.